FR1557677A - - Google Patents

Info

Publication number
FR1557677A
FR1557677A FR1557677DA FR1557677A FR 1557677 A FR1557677 A FR 1557677A FR 1557677D A FR1557677D A FR 1557677DA FR 1557677 A FR1557677 A FR 1557677A
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26253347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR1557677(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Application granted granted Critical
Publication of FR1557677A publication Critical patent/FR1557677A/fr
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/38Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR1557677D 1966-09-23 1967-09-25 Expired FR1557677A (en:Method)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB18383/67A GB1200886A (en) 1966-09-23 1966-09-23 Phenylaminoethanol derivatives
GB1838367 1967-04-21

Publications (1)

Publication Number Publication Date
FR1557677A true FR1557677A (en:Method) 1969-02-21

Family

ID=26253347

Family Applications (2)

Application Number Title Priority Date Filing Date
FR122101A Expired FR8010M (en:Method) 1966-09-23 1967-09-25
FR1557677D Expired FR1557677A (en:Method) 1966-09-23 1967-09-25

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR122101A Expired FR8010M (en:Method) 1966-09-23 1967-09-25

Country Status (15)

Country Link
US (3) US3644353A (en:Method)
AT (1) AT280996B (en:Method)
BE (1) BE704037A (en:Method)
CH (1) CH492676A (en:Method)
CS (1) CS167874B2 (en:Method)
CY (1) CY713A (en:Method)
DE (1) DE1643224C3 (en:Method)
DK (1) DK133618B (en:Method)
FR (2) FR8010M (en:Method)
GB (1) GB1200886A (en:Method)
IL (1) IL28643A (en:Method)
NL (2) NL160805C (en:Method)
NO (1) NO126014B (en:Method)
PL (1) PL70430B1 (en:Method)
SE (1) SE354061B (en:Method)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2128258A1 (de) * 1970-06-17 1971-12-23 Allen and Hanburys Ltd , London Optische Enantiomere von alpha hoch 1 tert Butylaminomethyl 4 hydroxy m xylylen alpha hoch 1, alpha hoch 3 diol, Verfahren zu ihrer Herstellung und Arzneipraparate
FR2319334A1 (fr) * 1975-07-29 1977-02-25 Allen & Hanburys Ltd Composes ayant une activite stimulatrice des recepteurs beta-adrenergiques
US4012444A (en) * 1969-07-08 1977-03-15 Allen & Hanburys Limited 5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof
EP0002867A1 (en) * 1977-12-27 1979-07-11 Technobiotic Ltd. 5-(2-Anilinoalkylamino-1-hydroxyalkyl)salicylamides, their preparation and anti-hypertensive compositions containing them
FR2430410A1 (fr) * 1978-07-03 1980-02-01 Lilly Co Eli Phenethanolamines et compositions pharmaceutiques en contenant
US4950783A (en) * 1978-09-20 1990-08-21 Schering Corporation Treatment of hypertension

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1957706C3 (de) * 1968-11-18 1978-06-29 Pfizer Corp., Colon (Panama) Kernsubstituierte 3-Phenoxy-l-phenoxyalkylamino-propan-2-ole und Arzneimittel auf deren Basis
US4101579A (en) * 1969-02-06 1978-07-18 Allen & Hanburys Limited Phenethanolamine ethers
GB1266058A (en:Method) * 1969-07-08 1972-03-08
AT310146B (de) * 1971-04-26 1973-09-25 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen N,N'-Bis-(β-hydroxyaryläthyl)-diaminoalkanen und deren Säureadditionssalzen
BE794414A (fr) * 1972-01-25 1973-07-23 Sandoz Sa Nouveaux amino-alcools, leur preparation et leur application comme medicament
US4018825A (en) * 1972-07-27 1977-04-19 Warner-Lambert Company 5-Hydroxy-α-(substituted aminomethyl)-m-xylene-α,α'-diols
US4024255A (en) * 1973-04-05 1977-05-17 Allen & Hanburys Limited Tetrazole containing naphthyridine-3-carboxamides
US4000192A (en) * 1973-05-07 1976-12-28 Allen & Hanburys Limited Pharmacologically active compounds
GB1468673A (en) * 1973-05-07 1977-03-30 Allen & Hanburys Ltd Substituted benzamides
US3883560A (en) * 1973-07-05 1975-05-13 Colgate Palmolive Co Salicylamidophenethanolamines
US4046913A (en) * 1973-08-18 1977-09-06 Boehringer Ingelheim Gmbh 1-(M-alkanoyloxy-phenyl)-1-hydroxy-2-(N-lower alkyl-amino)-ethanes and salts thereof
US4026897A (en) * 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
US4093628A (en) * 1974-04-18 1978-06-06 American Home Products Corporation Thiophene ethanolamines
US4012528A (en) * 1974-06-03 1977-03-15 Smithkline Corporation α-AMINOALKYL-3-(1,2-DIHYDROXYETHYL)-4-HYDROXY-BENZYL ALCOHOLS HAVING β-ADRENERGIC STIMULANT ACTIVITY
US4173583A (en) * 1975-04-17 1979-11-06 Schering Corporation Diastereoisomers of 5-(1-hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide
US4160036A (en) * 1975-07-29 1979-07-03 Allen & Hanburys Limited 4-Hydroxy-1,3-benzenedimethanol derivatives
US4154761A (en) * 1976-02-09 1979-05-15 Allen & Hanburys Limited Pharmacologically active compounds
JPS52113934A (en) * 1976-03-19 1977-09-24 Eisai Co Ltd Phenethylamine derivatives and bronchodilator containing the same
US4055658A (en) * 1976-05-17 1977-10-25 Mead Johnson & Company Cyanomethylphenethanolamines
US4127674A (en) * 1977-03-21 1978-11-28 Allergan Pharmaceuticals, Inc. Method of treatment for glaucoma
DE2833140A1 (de) * 1978-07-28 1980-02-07 Boehringer Sohn Ingelheim Neue n-substituierte heterocyclen
DE2935062A1 (de) * 1978-09-06 1980-03-20 Degussa Substituierte aminoalkylguanidine, deren herstellung und arzneimittel
US4590210A (en) * 1979-03-09 1986-05-20 Langham Maurice E Compositions for treatment of ocular hypertension
US4275074A (en) * 1979-03-09 1981-06-23 Graham J. Dobbie Catecholamine treatment of ocular hypertension
IT1148741B (it) * 1980-11-28 1986-12-03 Zambeletti Spa L Procedimento per la preparazione dell'1-(3,5-dimetossi-4-idrossifenil)-2-(n-metilammino)etanolo cloridrato
US4358455A (en) * 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
US4486446A (en) * 1980-12-23 1984-12-04 Merck & Co., Inc. Aralkylaminoethanol heterocyclic compounds
US4348398A (en) * 1980-12-23 1982-09-07 Merck Sharp & Dohme (I.A.) Corp. Quinolinyl ethanolamines
US4379166A (en) * 1981-08-03 1983-04-05 Schering Corporation Arylmethoxy-, arylmethylthio-, heteroarylmethoxy-, and heteroarylmethylthio-alkylaminoalcohols
CA1219865A (en) * 1982-05-14 1987-03-31 Leo Alig Aziridine phenethanolamine derivatives
US4594359B1 (en) * 1982-05-27 1994-07-26 Glaxo Group Ltd Pharmaceutical compositions
CH656308A5 (fr) * 1982-05-27 1986-06-30 Glaxo Group Ltd Compositions pharmaceutiques contenant du salbutamol.
GB2120942B (en) * 1982-05-27 1985-10-30 Glaxo Group Ltd Salbutamol compositions
CA1258454A (en) * 1982-08-10 1989-08-15 Leo Alig Phenethanolamines
EP0103830A3 (de) * 1982-09-22 1985-07-31 Bayer Ag Wachstumsfördernde Phenylethylamin-Derivate
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4499108A (en) * 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
US4751071A (en) * 1983-12-01 1988-06-14 Alza Corporation Composition comprising salbutamol
US4777049A (en) * 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
US4851229A (en) * 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
IL74940A (en) * 1984-04-17 1988-06-30 Glaxo Group Ltd Phenethanolamine compounds,their preparation and pharmaceutical compositions containing them
US4853381A (en) * 1984-04-17 1989-08-01 Glaxo Group Limited Ethanolamine compounds
JPS6183147A (ja) * 1984-09-28 1986-04-26 Nippon Chemiphar Co Ltd 新規なアミノアルコール誘導体およびその製造法並びにそれを有効成分とするグルタミン酸遮断剤
US5250546A (en) * 1984-09-28 1993-10-05 Nippon Chemiphar Co., Ltd. Amino-alcohol derivatives and processes for their preparation
EP0259159A3 (en) * 1986-09-05 1989-08-09 Schering Corporation Method for the preparation of alpha1- [[(1,1-Dimethylethyl) amino] methyl]-4-hydroxy-1,3-benzenedimethanol, and intermediates used in its preparation
US4952729A (en) * 1986-09-05 1990-08-28 Schering-Plough Corp. Intermediates in the preparation of alpha1(((1,1-dimethylethyl) amino) methyl)-4-hydroxy-1,3-benzenedimethanol
US5011993A (en) * 1986-09-05 1991-04-30 Schering Corporation Method for the preparation of α1 [[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol
US5453418A (en) * 1988-03-07 1995-09-26 Eli Lilly And Company Ractopamine and growth hormone combinations
US5030640A (en) * 1989-01-05 1991-07-09 Merck & Co., Inc. Novel β-adrenergic agonists and pharmaceutical compositions thereof
US5166437A (en) * 1989-03-03 1992-11-24 Orion-Yhtyma Oy Process for the preparation of fluoxetine
GB8909273D0 (en) * 1989-04-24 1989-06-07 Glaxo Group Ltd Chemical compounds
YU48707B (sh) 1990-03-02 1999-07-28 Glaxo Group Limited Aparat za inhaliranje - inhalator
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
SK280967B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
US5118683A (en) * 1990-06-13 1992-06-02 Schering Corporation Esters of 4-hydroxy-1,3-benzenedimethanol and compositions and methods employing such compounds
AU8184091A (en) * 1990-06-13 1992-01-07 Schering Corporation Esters and cyclic diesters of 4-hydroxy-1,3-benzenedimethanol and compositions and methods employing such compounds
US5011845A (en) * 1990-06-13 1991-04-30 Schering Corporation Cyclic diesters of 4-hydroxy-1,3-benzenedimethanol and compositions and methods employing such compounds
IL99436A (en) * 1990-09-11 1999-03-12 Schering Corp Process for the preparation of albuterol, and hydrates of the intermediates arylglyoxal and their boron complex ariethanolamine
US5182097A (en) * 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
ZA924163B (en) 1991-06-10 1993-02-24 Schering Corp Non-chlorofluorocarbon aerosol formulations
DK0588897T3 (da) * 1991-06-10 1996-03-18 Schering Corp Aerosolformuleringer, der i det væsentlige er fri for chlorfluorcarbonforbindelser
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
DK1086688T3 (da) 1991-12-18 2004-08-16 Minnesota Mining & Mfg Aerosolformuleringer til suspensioner
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5475138A (en) * 1994-07-07 1995-12-12 Pharm-Eco Laboratories Incorporated Method preparing amino acid-derived diaminopropanols
CA2217954C (en) 1995-04-14 2005-02-15 Glaxo Wellcome Inc. Metered dose inhaler for salmeterol
EP1870122A3 (en) * 1995-04-14 2008-03-12 SmithKline Beecham Corporation Metered dose inhaler
EP0820322B1 (en) 1995-04-14 2002-07-10 SmithKline Beecham Corporation Metered dose inhaler for fluticasone propionate
US5603918A (en) * 1995-06-09 1997-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. Aerosol composition of a salt of ipratropium and a salt of albuterol
US5770615A (en) * 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
EP0801060A1 (en) * 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
US20030103906A1 (en) * 1997-10-14 2003-06-05 Smithkline Beecham Corporation Metered dose inhaler having internal surfaces coated with fluorocarbon polymer
ZA994264B (en) * 1998-07-01 2000-01-25 Warner Lambert Co Stereoisomers with high affinity for adrenergic receptors.
US7232837B2 (en) * 1999-06-29 2007-06-19 Mcneil-Ppc, Inc. Stereoisomers with high affinity for adrenergic receptors
GB0030171D0 (en) 2000-12-11 2001-01-24 Cipla Ltd Process for preparing isomers of salbutamol
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
JPWO2003106418A1 (ja) * 2002-06-12 2005-10-13 住友製薬株式会社 インドール、インダゾール、およびベンズアゾール類
DE10249576B3 (de) * 2002-10-24 2004-04-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von (R)-Salbutamol
US20040127733A1 (en) 2002-10-31 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
DE10251170A1 (de) * 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DK1572622T3 (da) * 2002-12-10 2006-08-28 Sepracor Inc Anvendelse af levalbuterol-L-tartrat ved fremstilling af en doseringsinhalator
TW200418825A (en) * 2002-12-16 2004-10-01 Hoffmann La Roche Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives
AU2004242777B2 (en) * 2003-05-30 2011-05-12 Ranbaxy Laboratories Limited Substituted pyrrole derivatives and their use as HMG-Co inhibitors
JP2007504123A (ja) * 2003-08-29 2007-03-01 ランバクシー ラボラトリーズ リミテッド Iv型ホスホジエステラーゼの阻害剤
EP1663159A4 (en) * 2003-09-10 2010-06-09 Map Pharmaceuticals Inc AEROSOL FORMULATIONS FOR THE DELIVERY OF DIHYDROERGOTAMINE TO THE SYSTEMIC CIRCULATION BY PULMONARY INHALATION
CA2542530A1 (en) * 2003-10-20 2005-05-12 Schering Corporation Pharmaceutical aerosol compositions
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EP1577292A1 (en) * 2004-03-17 2005-09-21 Pfizer Limited Phenylaminoethanol derivatives as beta2 receptor agonists
DE102004021779A1 (de) 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2007008427A2 (en) * 2005-07-08 2007-01-18 Xemplar Pharmaceuticals, Llc Aerosol compositions and methods
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
RU2008119322A (ru) * 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Композиции ингибиторов фосфодиэстеразы iv типа
DE102005052127A1 (de) 2005-10-28 2007-05-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue indol-haltige Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
CN100398512C (zh) * 2006-04-21 2008-07-02 华南农业大学 (±)α-[(取代胺基)甲基]-苯环取代基-苯甲醇类化合物的制备方法
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
DK2074093T3 (da) 2006-08-22 2012-11-19 Ranbaxy Lab Ltd Fremgangsmåde til fremstilling af matrix metalloproteinase-inhibitorer og chirale hjælpemidlerdel dertil
CA2664247A1 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
EP2066661A2 (en) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2538082T3 (es) * 2007-02-11 2015-06-17 Map Pharmaceuticals Inc Método de administración terapéutica de DHE para permitir el rápido alivio de migraña mientras que se minimiza el perfil de efectos secundarios
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
MX2009009793A (es) 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
MX354184B (es) 2007-10-05 2018-02-16 Acucela Inc Compuestos alcoxi para el tratamiento de enfermedades.
ES2320961B1 (es) 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
CN101575298B (zh) * 2008-12-31 2013-03-06 上海予利化学科技有限公司 一种制备手性医药中间体2-氨基-1-苯乙醇的方法
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
EP2448569B1 (en) * 2009-07-02 2021-10-27 Acucela, Inc. Pharmacology of visual cycle modulators
WO2012014114A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
MX2013003364A (es) 2010-09-24 2013-06-05 Ranbaxy Lab Ltd Inhibidores de metaloproteinasa de matriz.
CN102584609B (zh) * 2011-01-06 2015-05-27 上海医药工业研究院 一种沙美特罗的制备方法
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
CN104703598A (zh) 2012-01-20 2015-06-10 奥克塞拉有限公司 用于疾病治疗的取代的杂环化合物
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
CN103086916B (zh) * 2012-10-10 2015-06-24 淮海工学院 席夫碱功能化的双子离子液体
CN102924382B (zh) * 2012-10-10 2014-11-19 淮海工学院 双水杨醛功能化的咪唑型双子离子液体及其制备方法
CA2891234C (en) 2012-12-03 2017-03-07 Pfizer Inc. Selective androgen receptor modulators
EP3042892A1 (en) 2015-01-09 2016-07-13 Deva Holding Anonim Sirketi Amorphisation of levosalbutamol tartrate
CN108947831A (zh) * 2018-07-13 2018-12-07 重庆康刻尔制药有限公司 一种沙丁胺醇中间体ⅲ的纯化方法
CN108623486A (zh) * 2018-07-13 2018-10-09 重庆康刻尔制药有限公司 一种沙丁胺醇中间体ⅴ盐酸盐的制备方法
CN112479908B (zh) * 2020-11-26 2025-05-27 江西天戌药业有限公司 一种硫酸沙丁胺醇杂质d的制备方法
CN112920064A (zh) * 2021-05-11 2021-06-08 仁合诚益医药技术(天津)有限公司 一种沙丁胺醇杂质化合物及其制备方法、检测方法和用途
WO2023283441A1 (en) 2021-07-09 2023-01-12 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery
CN114159385A (zh) * 2021-09-27 2022-03-11 北京四环科宝制药股份有限公司 含有硫酸沙丁胺醇的药物组合物及其制备方法
WO2023119093A1 (en) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery
GB202304652D0 (en) * 2023-03-29 2023-05-10 Atrogi Ab New compounds and medical uses thereof
CN116283619A (zh) * 2023-03-30 2023-06-23 河北广祥制药有限公司 一种硫酸沙丁胺醇杂质及其制备方法

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4012444A (en) * 1969-07-08 1977-03-15 Allen & Hanburys Limited 5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof
DE2128258A1 (de) * 1970-06-17 1971-12-23 Allen and Hanburys Ltd , London Optische Enantiomere von alpha hoch 1 tert Butylaminomethyl 4 hydroxy m xylylen alpha hoch 1, alpha hoch 3 diol, Verfahren zu ihrer Herstellung und Arzneipraparate
FR2319334A1 (fr) * 1975-07-29 1977-02-25 Allen & Hanburys Ltd Composes ayant une activite stimulatrice des recepteurs beta-adrenergiques
EP0002867A1 (en) * 1977-12-27 1979-07-11 Technobiotic Ltd. 5-(2-Anilinoalkylamino-1-hydroxyalkyl)salicylamides, their preparation and anti-hypertensive compositions containing them
FR2430410A1 (fr) * 1978-07-03 1980-02-01 Lilly Co Eli Phenethanolamines et compositions pharmaceutiques en contenant
FR2430411A1 (fr) * 1978-07-03 1980-02-01 Lilly Co Eli Phenethanolamines et leur utilisation therapeutique
US4950783A (en) * 1978-09-20 1990-08-21 Schering Corporation Treatment of hypertension

Also Published As

Publication number Publication date
NL160805C (nl) 1979-12-17
IL28643A (en) 1971-12-29
CS167874B2 (en:Method) 1976-05-28
CY713A (en) 1973-11-26
NL6713016A (en:Method) 1968-03-25
US3642896A (en) 1972-02-15
DK133618C (en:Method) 1976-11-08
NL7809942A (nl) 1979-01-31
DE1643224C3 (de) 1979-08-09
CH492676A (de) 1970-06-30
GB1200886A (en) 1970-08-05
US3705233A (en) 1972-12-05
DK133618B (da) 1976-06-21
AT280996B (de) 1970-05-11
BE704037A (en:Method) 1968-02-01
US3644353A (en) 1972-02-22
NO126014B (en:Method) 1972-12-11
DE1643224B2 (de) 1978-11-23
FR8010M (en:Method) 1970-07-27
PL70430B1 (en) 1974-02-28
NL160805B (nl) 1979-07-16
SE354061B (en:Method) 1973-02-26
DE1643224A1 (de) 1972-03-02

Similar Documents

Publication Publication Date Title
DK133618C (en:Method)
AU5917865A (en:Method)
AU417216B2 (en:Method)
AU5895065A (en:Method)
AU612166A (en:Method)
AU6597365A (en:Method)
AU6703465A (en:Method)
BE674987A (en:Method)
BE666282A (en:Method)
BE692646A (en:Method)
BE692618A (en:Method)
BE692360A (en:Method)
BE692281A (en:Method)
BE690246A (en:Method)
BE689489A (en:Method)
BE685142A (en:Method)
BE677343A (en:Method)
BE675139A (en:Method)
BE693762A (en:Method)
BE674882A (en:Method)
BE674792A (en:Method)
BE674777A (en:Method)
BE674713A (en:Method)
BE693239A (en:Method)
BE662818A (en:Method)